Aetna Better Health of Virginia, a CVS Health® company, has pledged $400,000 to Restoration Housing to facilitate the acquisition of a property in Roanoke, Virginia. This property will be utilized by the Twelve Foundation, a nonprofit dedicated to assisting pregnant…
Kirby McInerney LLP is reminding investors of the upcoming May 28, 2024 deadline to seek lead plaintiff status in a federal securities class action related to bluebird bio, Inc. (NASDAQ: BLUE). The lawsuit concerns securities acquired during April 24, 2023,…
Today, ImmunityBio has announced the release of three podcasts in collaboration with UroToday, shedding light on the recent FDA approval of ANKTIVA® (N-803, also known as nogapendekin alfa inbakicept-pmln) alongside Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma…
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have forged a robust strategic alliance aimed at shaping the future landscape of global health and wellness. Drawing upon their respective proficiencies and groundbreaking research in coenzymes and NAD+, both entities are…
Azitra, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering innovative therapies for precision dermatology, has unveiled preclinical findings from its cutting-edge platform and pipeline. These findings are being presented at the Society of Investigative Dermatology (SID) 2024 Annual Meeting in…
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company with its lead non-viral program EG-70 undergoing pivotal trials for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), announced the election of Paul Hastings and Wouter Joustra to its Board of Directors…
Incyte Corporation (Nasdaq:INCY) announced today that its Board of Directors has greenlit a $2.0 billion share repurchase program. As part of this initiative, the company has initiated a modified “Dutch Auction” tender offer, aiming to buy back shares of its…
Eisai announced today that it has received approval in China for an additional indication of its antiepileptic drug (AED) Fycompa® (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients aged 12 years and older. Fycompa…
Revelation Biosciences, Inc. (NASDAQ: REVB), a clinical-stage life sciences firm dedicated to leveraging trained immunity for disease prevention and treatment, released its financial results for the three months ending March 31, 2024. Financial Highlights: As of March 31, 2024, the…
Today, governments worldwide have reaffirmed their commitment to advancing a proposed pandemic agreement, aiming to refine the draft in preparation for the Seventy-seventh World Health Assembly commencing on May 27, 2024. At the World Health Organization headquarters in Geneva, government…
Viatris has just announced its financial outcomes for the initial quarter of 2024, showcasing sustained progress and the robustness of its core operations. Executive Insights Scott A. Smith, CEO of Viatris, remarked, “Our impressive financial results for the first quarter…
argenx, a global leader in immunology dedicated to enhancing the lives of individuals grappling with severe autoimmune disorders, has unveiled its financial results for the first quarter of 2024 along with a comprehensive business update. Tim Van Hauwermeiren, Chief Executive…